Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea · Delayed Price · Currency is KRW 5,070.00
+1,065.00 (26.59%)
Sep 1, 2026, 3:30 PM KST
Vaxcell-Bio Therapeutics Revenue
In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth.
Revenue
1.90B
Revenue Growth
+13,737.28%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
117.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 1.89B | 13,737.28% |
| Dec 31, 2023 | 13.72M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Amicogen | 43.44B |
| GC Genome | 32.64B |
| Prestige BioPharma | 16.21B |
| GeneOne Life Science | 12.37B |
| Anterogen.Co.,Ltd. | 8.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |